All the events here are relevant to people working in dementia research. If you would like to add your own you can submit an event
- This event has passed.
IMPACT-AD – Clinical Trials Training
25/08/2024 - 30/08/2024
Alzheimer’s disease clinical trials Alzheimer’s disease clinical trials Alzheimer’s disease clinical trials
Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD
Welcome letter from the Course Directors
Thank you for your interest in the IMPACT-AD Course.
Alzheimer’s Disease and Related Disorders (ADRD) are public health crises and critical areas of scientific effort. The National Institutes of Health, Alzheimer’s Association, and other federal, state, and non-profit funders of research are investing heavily in the science of ADRD in an effort to curb the impact of these debilitating, burdensome, and costly disorders. Tremendous advances made in understanding the pathobiology of disease will ultimately have one final pathway to impacting clinical care and public health – randomized controlled clinical trials.
IMPACT-AD was founded to train the next generation of ADRD clinical trialists, to ensure that investments in discovery yield outcomes for patients and families. Our goal is to provide education and tools to establish a national cohort of qualified investigators to guide the field toward improved therapies. Equally importantly, we are focused on diversifying the ADRD trial workforce. This diversity is manifold: it includes the demographic characteristics of investigators (age, race, ethnicity, etc.), but also their specialties (physicians, psychologists, statisticians, etc.), backgrounds (rural, urban, etc.), and career stage or current position (current AD Clinical Trial Consortium (ACTC) site, non-ACTC academic site, non-academic site). IMPACT-AD will be successful if it produces an outstanding, well-trained, diverse, and knowledgeable cohort of collaborative investigators who will carry the mantle of the National Plan to Address AD.
IMPACT-AD will leverage the outstanding collection of investigators, including members of the ACTC and beyond. National and international leaders in ADRD trials will gather annually to provide a unique, interactive, cutting edge educational experience in ADRD trials. We offer two tracks for those interested in advancing their careers in ADRD trials.
Professionals Track
This track seeks applications from individuals with at least 2 years of experience in ADRD research and/or clinical trials (in a broad variety of roles including, but not limited to clinicians, study coordinators, psychometricians, and other study professionals) who wish to further their knowledge and advance their careers in ADRD trials.
Fellowship Track
This track seeks applications from individuals seeking to serve as Principal Investigators in ADRD trials and offers mentored training in protocol development. Applications are open to individuals in their last year of doctoral training, currently in fellowship or postdoctoral training, faculty members or the equivalent positions.
Goals of the Course
To provide early-stage investigators and those new to AD trials with a unique, comprehensive, and active learning experience in ADRD trials.
This will be accomplished by leveraging the full infrastructure and expertise of the Alzheimer’s Clinical Trials Consortium (ACTC) to enable a diverse range of clinicians, scientists and researchers to receive modern and robust training on ADRD clinical trials.
IMPACT-AD is an Alzheimer’s Disease and related disorders (ADRD) course that aims to educate and promote diversity among research professionals and future principal investigators in the field of ADRD research.
- Lectures will be given by national leaders in ADRD trials, and attendees will have the opportunity to work closely with the field’s top investigators in small group workshops.
- IMPACT-AD emphasizes diversity of trainees, interactive learning, a cooperative culture among alumni and long-term metrics of success.
- The course will be free to those who attend and will count as CME credit.
